UPDATE 1-Dyax posts narrower-than-expected Q2 loss

* Q2 loss/shr $0.05 vs est. loss/shr $0.13

* Q2 rev $15.1 mln vs est. $7.3 mln

July 28 (Reuters) - Dyax Corp (DYAX.O) reported a narrower-than-expected quarterly loss, helped by strong sales of its genetic-disorder drug Kalbitor and higher development and license fee revenue.

For the second quarter, the biotechnology firm reported a loss of $5.3 million, or 5 cents per share, compared with a loss of $14.4 million, or 23 cents per share, in the year-ago period.

Revenue jumped three fold to $15.1 million, of which $13.8 million was recognized after Cubist Pharmaceuticals Inc (CBST.O) ended the development of the drug DX-88 (ecallantide) in March.[nSGE62U1PD]

Cubist had licensed the experimental treatment, ecallantide, to reduce blood loss in patients undergoing cardiac surgery, from Dyax (DYAX.O).

Sales of Kalbitor jumped 55 percent over the sequential quarter, when the drug was launched.

Analysts on average were expecting the company to post a loss of 13 cents a share, on revenue of $7.3 million for the quarter, according to Thomson Reuters I/B/E/S.

Shares of Dyax closed at $2.53 Tuesday on Nasdaq. (Reporting by Shailesh Kuber in Bangalore; Editing by Vyas Mohan)